论文部分内容阅读
目的观察奈达铂(NDP)联合羟基喜树碱(HCPT)治疗晚期食管癌的近期疗效和不良反应。方法46例晚期食管癌患者采用奈达铂(NDP)80~100mg/m2,静脉滴注,第1天;羟基喜树碱(HCPT)6mg/m2,静脉滴注,第1~5天。28天为1个周期。化疗2个周期后评价近期疗效和不良反应。结果46例均可评价,总有效率为71·7%。26例初治患者中,有效率73·1%;20例复治患者中,有效率70·0%,两组差异无统计学意义(P>0·05)。主要不良反应为胃肠道反应和血液学毒性,胃肠道反应均为Ⅰ~Ⅱ度,发生率为37·0%(17/46);血液学毒性方面为白细胞和血小板减少,Ⅲ+Ⅳ度发生率分别为13·0%(6/46)和6·5%(3/46)。结论奈达铂联合羟基喜树碱治疗晚期食管癌近期疗效高,毒副作用可以耐受。
Objective To observe the short-term efficacy and side effects of NDP combined with hydroxycamptothecin (HCPT) in the treatment of advanced esophageal cancer. Methods Forty-six patients with advanced esophageal cancer were treated with NDP 80 ~ 100 mg / m2, intravenous drip on the first day and HCPT 6 mg / m2 on the 1st ~ 5th day. 28 days for a period. Evaluation of short-term efficacy and adverse reactions after 2 cycles of chemotherapy. Results 46 cases were evaluable, the total effective rate was 71.7%. Of the 26 newly diagnosed patients, the effective rate was 73.1%. Among the 20 retreatment patients, the effective rate was 70.0%. There was no significant difference between the two groups (P> 0.05). The main adverse reactions were gastrointestinal reaction and hematological toxicity. The gastrointestinal reactions were grade Ⅰ ~ Ⅱ, the incidence rate was 37.0% (17/46). The hematological toxicities were leukopenia and thrombocytopenia. Ⅲ + Ⅳ The incidence rates were 13.0% (6/46) and 6.5% (3/46), respectively. Conclusion Nedaplatin and hydroxycamptothecin treatment of advanced esophageal cancer with high efficacy recently, toxic side effects can be tolerated.